Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
admission, AllocetraTM, Allocetra™for, Allocetra™to, Allocetra™would, anti, APACHEII, BGU, CEO, contractor, coping, COSO, coupled, depict, deviate, died, embedded, exceeded, finder, foremost, gender, goal, Haddasah, hard, Hershkovitz, ICU, IIb, Italy, Jumpstart, legacy, mandatorily, markedly, meant, multiplied, Negev, noncontrolling, nonpublic, obesity, omitted, OTS, proportionate, purposefully, QP, rescheduled, residual, room, ROU, Sep, Sequential, simply, slowest, SOFA, Spain, spouse, surfaced, swift, Thirty, tort, uncertificated, unpermitted, USD, Wuhan
Removed:
abovementioned, allocation, attractive, bona, cGLP, commenced, Dalia, deed, defect, defector, deposit, deter, disqualification, disqualified, execution, fide, filer, fit, forward, fulfill, hereinafter, inventor, leasehold, motor, peer, postpone, prepaid, reflecting, remeasured, rendering, retrospectively, revised, rotation, seniority, thousand, undermine, waiving
Filing tables
Filing exhibits
- 20-F Annual report (foreign)
- 2.1 Description of Ordinary Shares
- 4.3 Enlivex Therapeutics LTD. 2019 Global Share Incentive Plan
- 4.8 Employment Agreement Between the Company and Oren Hershkovitz, Dated As of November 16, 2019
- 4.15 Research Agreement, Between the Company and Cell Generation (C-G) LTD., Dated May 12, 2019
- 8.1 List of Subsidiaries of Enlivex Therapeutics LTD
- 12.1 Certification
- 12.1 Certification
- 13.1 Certification
- 13.2 Certification
- 15.1 Consent of Consent of Yarel + Partners
- Download Excel data file
- View Excel data file
ENLV similar filings
Filing view
External links
Exhibit 13.2
CERTIFICATION PURSUANT TO
18 U.S.C. Section 1350
In connection with the filing of the Annual Report on Form 20–F for the period ended December 31, 2019 (the “Report”) by Enlivex Therapeutics Ltd. (the “Company”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Shachar Shlosberger | |
Shachar Shlosberger | |
Chief Financial Officer | |
April 30, 2020 |